LENZ Q2 Revenue Hits $5.5M on VIZZ Growth, Loss Widens to $31.9M
LENZ sits 17% above its 52-week low of $4.68.
Summary
LENZ Therapeutics reported Q2 2026 revenue of $5.5 million, driven by VIZZ eye drop sales and license payments from international deals. Product sales rose 9% sequentially, with over 60% of ePharmacy patients refilling and early cohorts tracking to five packs per year. The net loss widened to $31.9 million as launch and marketing costs ramped up, including July telehealth and TV campaigns. This is the first detailed look at VIZZ's commercial traction since the Q1 report showed initial sales and $258.4 million in cash. The revenue ramp and refill data suggest early adoption, but the lack of guidance leaves the path to profitability unclear.
At the time of this announcement, LENZ was trading at $5.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.4M. The 52-week trading range was $4.68 to $50.40. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.